Andrey Borisovich Ryabov’s research while affiliated with Federal Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (1)


Tamoxifen Never Ceases to Amaze: New Findings on Non-Estrogen Receptor Molecular Targets and Mediated Effects
  • Literature Review

May 2018

·

95 Reads

·

26 Citations

Cancer Investigation

Tatiana Anatolievna Bogush

·

Boris Borisovich Polezhaev

·

Ivan Andreevich Mamichev

·

[...]

·

Andrey Borisovich Ryabov

Tamoxifen is a first targeted drug that continues to be the gold standard in treatment of estrogen receptor positive breast cancer for almost 50 years. The current review is an update of the paper published in 2012. We provide the new data on the tamoxifen targets that are the key points of signaling cascades activating cellular proliferation, which determines aggressiveness of disease and chemotherapy resistance or sensitivity. Some inspiring clinical cases dealing with tamoxifen efficiency in treatment of different tumors are discussed. Additionally, the review includes data on antiviral, antibacterial, antifungal and antiparasitic activity of tamoxifen

Citations (1)


... Hormone therapy (32)(33)(34)(35)(36) is extensively employed in the treatment of hormone-dependent breast tumors, either as a monotherapy or more frequently in combination with chemotherapy or radiotherapy. While the action of most chemotherapy drugs is linked to DNA damage, the exact role of DNA damage in influencing the estrogen receptor machinery in tumor cells remains unclear. ...

Reference:

Irreversible inhibition of estrogen receptor α signaling and the emergence of hormonal resistance in MCF7 breast cancer cells induced by DNA damage agents
Tamoxifen Never Ceases to Amaze: New Findings on Non-Estrogen Receptor Molecular Targets and Mediated Effects
  • Citing Article
  • May 2018

Cancer Investigation